ArTS Archivio della ricerca di Trieste
ArTS è il sistema di gestione integrata dei dati della ricerca adottato dall' Università degli Studi di Trieste
EnglishIntroduction: Renal cell carcinoma (RCC) accounts for 2–3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC. Areas covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma. Expert opinion: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy.
| Titolo: | Lenvatinib for the treatment of renal cell carcinoma |
| Autori: | |
| Data di pubblicazione: | 2018 |
| Stato di pubblicazione: | Pubblicato |
| Rivista: | |
| Abstract: | Introduction: Renal cell carcinoma (RCC) accounts for 2–3% of all solid tumors. Expression of the receptor for the vascular endothelial growth factor (VEGF) is one of the most common features of RCC. Areas covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid tumors. It has shown promising results in the treatment of RCC, especially when combined with everolimus, In this review, we summarize the available data of lenvatinib for the treatment of advanced/metastatic renal cell carcinoma. Expert opinion: Lenvatinib in combination with everolimus has provided encouraging results in both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of approach it would be interesting in future clinical settings testing also the combination of lenvatinib and everolimus with immune-therapy. |
| Handle: | http://hdl.handle.net/11368/2961370 |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1080/13543784.2018.1472235 |
| Appare nelle tipologie: | 1.1 Articolo in Rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| roviello2018.pdf | Bozza finale post-referaggio (post-print) | Digital Rights Management non definito | Open Access Visualizza/Apri | |
| Expert opinion on investigational drugs-2-8.pdf | Documento in Versione Editoriale | Copyright Editore | Administrator Richiedi una copia | |
| Lenvatinib for the treatment of renal cell carcinoma.pdf | Bozza finale post-referaggio (post-print) | Copyright Editore | Open Access Visualizza/Apri | |
| Lenvatinib for the treatment of renal cell carcinoma.pdf | Documento in Versione Editoriale | Copyright Editore | Administrator Richiedi una copia |
